Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4007 Inactivation of PHLDA3 gene leading to tumorigenesis of pancreatic neuroendocrine tumors and its molecular mechanisms

Introduction: The molecular mechanism underlying the tumorigenesis of sporadic pancreatic neuroendocrine tumors (PNETs) is largely unknown. Our previous studies showed that loss of heterozygosity (LOH) at chromosome 1q31 (including PHLDA3 gene) was frequently found in sporadic PNETs (2005 insulinoma and 2003 gastrinoma, respectively).

Conference:

Presenting Author: Song Y

Authors: Song Y, Tong W, Wang Z, Chen Y,

Keywords: pancreatic neuroendocrine tumor, PHLDA3, tumorigenesis, prognosis,

#3804 Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response

Introduction: Temozolomide (TMZ) is an alkylating agent and is widely used in the treatment of PanNET. So far, only the MGMT status, defined by its immunohistochemical (IHC) expression or its promoter methylation, has been proposed as predictor of response to TMZ, but its value remains controversial.

Conference:

Presenting Author: Marinoni I

Authors: Cives M, Kirchner P, Palmirotta R, Lauricella E, de Mestier L,

Keywords: PanNET, Temozolomide, MGMT,

#3296 Effect of different expression status of MGMT on the efficacy of temozolomide in gastroenteropancreatic neuroendocrine tumors

Introduction: Temozolomide (TMZ) based chemotherapy on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) seems effective, but the predictive effect of 06-methylguanine DNA methyltransferase (MGMT) on efficacy is controversial.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Li Y, Qi Z, Tan H,

Keywords: neuroendocrine tumor, chemotherapy, MGMT, Temozolomide,

#3211 Microscopic resection margin status does not predict long-term survival in small bowel neuroendocrine tumors

Introduction: Small bowel neuroendocrine tumors (SBNETs) are increasing in incidence and are the most common small bowel malignancy. The characteristic nodal mass, which may extend high into the mesentery, can make achieving microscopically negative resection margins difficult without resecting excessive lengths of small bowel.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mentor K, Ammar K, Thakkar R, Farrington E, Buckley E,

Keywords: small bowel, grading, resection margin, survival,